Understanding how genetics and social factors affect clopidogrel response in Puerto Ricans
Official title: Social, Genomic, and Epigenomic Drivers of Clopidogrel Response in Puerto Ricans
Funded at Northwestern University at Chicago · NIH-10981740 · Data updated 2026-11-12
This study is looking at how genetics and social factors affect how well the heart medication clopidogrel works for Puerto Rican patients with coronary artery disease, aiming to better understand their unique responses to the treatment.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Northwestern University at Chicago NIH-funded |
| Lab location | 1 site (Chicago, United States) |
| Project start | September 20, 2024 |
| Project end | June 30, 2025 |
| Funding year | 2024 |
| Award (this year) | $745,930 |
| NIH project number | 1R01HG013773-01 |
| Project ID | NIH-10981740 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are Puerto Rican individuals who are prescribed clopidogrel for coronary artery disease.
✕Less likely to help
Patients who are not of Puerto Rican descent or those who do not take clopidogrel may not benefit from this research.
What this research studies
This research investigates how genetic variations and social determinants of health influence the effectiveness of clopidogrel, a medication used to treat coronary artery disease, specifically in Puerto Rican populations. The study aims to create a comprehensive dataset that includes genomic, transcriptomic, and epigenomic information to better understand how these factors affect patient responses to the drug. By focusing on admixed Caribbean Hispanics, the research seeks to fill a gap in knowledge regarding how non-European populations respond to clopidogrel. The team will also explore how social factors impact healthcare outcomes in this community.
Why it matters
Potential benefit: If successful, this research could lead to more personalized and effective treatment strategies for Puerto Rican patients taking clopidogrel.
How similar studies have gone: Previous pharmacogenomic studies have shown success in improving treatment outcomes in other populations, but this specific focus on Puerto Ricans is novel.
Where this research is happening
-
Northwestern University at Chicago
Chicago, United States Active
Researchers
- Principal investigator: Perera, Minoli a — Northwestern University at Chicago
- Study coordinator: Perera, Minoli a
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.